BioMap

What BioMap does

BioMap is a life sciences AI company that builds foundation models and a closed-loop discovery platform for biopharmaceutical R&D. Its core asset is xTrimo V4, a 268-billion-parameter foundation model trained on multi-modal biological data spanning DNA, RNA, proteins, cells, chemistry, multi-cells, and biosystems, and positioned by the company as the first foundation model purpose-built for decoding biological systems. BioMap commercializes this capability through BioMap OS, a dry-wet closed-loop life science discovery system that integrates knowledge aggregation, predictive design, experimental control, and model training, and is deployable as standalone models, software, or full systems in cloud or on-premises configurations. The platform targets four verticals: antibody and protein discovery, innovative therapies and precision medicine, synthetic biology, and frontier scientific research. Validated use cases include de novo protein design, multi-objective optimization with precise epitope control, and AI-driven target identification.

BioMap operates as an enterprise B2B company serving multinational corporations, Fortune Global 500 companies, and industry leaders, with reported traction of 800+ institutional users, 30+ leading enterprise customers, 60+ proof-of-concept programs, and 40+ delivered antibody and protein programs. Revenue is generated through two channels: system licensing of BioMap OS (and underlying xTrimo components) for independent client workflows, and BioMap-conducted discovery services covering antibody discovery, protein discovery, and other specialized life science programs. Pricing is custom and not publicly disclosed. The company has secured named partnerships at the flagship tier (Sanofi for AI-driven drug discovery) and a strategic joint venture at the core tier (MegaStream TechBio with Harbour BioMed) that integrates xTrimo into a dedicated biologics pipeline business. The company was founded in 2019 by Baidu founder Robin Li and former Baidu Ventures CEO Liu Wei, is incorporated in China with operating presence in Palo Alto, and has filed confidentially for a Hong Kong IPO targeting a raise of several hundred million US dollars.

Name

BioMap

Legal name

BioMap

Website

https://biomap.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

BioMap builds xTrimo V4, a 268-billion-parameter foundation model for life sciences, and BioMap OS, a closed-loop AI discovery platform, licensed to and used by multinational pharmaceutical companies for antibody, protein, and therapeutic target discovery.

Ownership category

akta.pro rank

Product category

AI Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

Keywords

• Life science AI
• Foundation models
• Drug discovery
• Protein design
• Biologics research

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. System Licensing: BioMap OS can be deployed as models, software, or a complete system with configurable professional components, supporting cloud and on-premises deployment. This represents the primary commercial licensing model.
2. Discovery Services: System-based discovery services including protein discovery and antibody discovery, where BioMap conducts discovery on behalf of clients in areas such as antibody and protein, innovative therapies and precision medicine, synthetic biology, and frontier scientific research.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

BioMap builds and licenses AI foundation models and an integrated life science discovery platform (BioMap OS) powered by the proprietary 268-billion-parameter xTrimo V4 foundation model. The platform delivers a dry-wet closed-loop discovery system for protein and antibody design, novel target identification, and therapeutic discovery, with both licensing and fee-based discovery services for enterprise pharmaceutical and biotech customers.

Product overview

BioMap offers a unified platform architecture centered on BioMap OS, an AI-driven life science discovery system powered by the xTrimo V4 foundation model (268 billion parameters). The platform provides modular functionality including knowledge aggregation, predictive design, experimental control, and model training, with deployment options as models, software, or complete systems. BioMap OS serves four verticals: antibody and protein discovery, innovative therapies and precision medicine, synthetic biology, and frontier scientific research, with configurable professional components supporting both cloud and on-premises deployment.

Differentiator

Problem solved

Functional benefit

Brands

• xTrimo: BioMap's 268-billion-parameter life science foundation model for decoding biological systems, achieving 300+ state-of-the-art performances across 20+ fields.
• BioMap OS
• MegaStream TechBio

Products and services

• BioMap OS AI-driven intelligent R&D platform powered by xTrimo foundation models, providing a dry-wet closed-loop life science discovery system that integrates knowledge aggregation, predictive design, experimental control, and model training for enterprise pharmaceutical and biotech customers conducting antibody/protein discovery, innovative therapies, synthetic biology, and frontier scientific research.
• xTrimo V4 Foundation Model World's first 268-billion-parameter life science foundation model that demonstrates cross-modal reasoning across DNA, RNA, proteins, cells, chemistry, multi-cells, and biosystems, achieving 300+ state-of-the-art model performances across 20+ fields, available for licensing as part of the BioMap OS offering to enterprise customers.
• System-Based Discovery Services Fee-based discovery services offered by BioMap to enterprise clients, including protein discovery and antibody discovery, where BioMap conducts discovery on behalf of clients in areas such as antibody and protein, innovative therapies and precision medicine, synthetic biology, and frontier scientific research using the BioMap OS platform.

Quantifiable outcome

• 300+ State-of-the-Art model performances across 20+ fields
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• Harbour BioMedcoreStrategic or Co-development Partner · 15 June 2026Long-term strategic partnership to jointly launch MegaStream TechBio, an AI-native pipeline company focused on complex biologics drug discovery. MegaStream combines Harbour BioMed's fully human antibody platform (Harbour Mice) and clinical development capabilities with BioMap's xTrimo foundation models. The entity prioritizes First-in-Class and Best-in-Class assets across cardiovascular, renal, oncology, and anti-aging areas, with projected 500%+ efficiency gains and 5+ petabytes of data generation within five years.
• SanofiflagshipStrategic or Co-development PartnerBioMap previously partnered with French drugmaker Sanofi for AI-driven drug discovery applications utilizing the xTrimo foundation models. Sanofi has articulated a comprehensive strategy to become the first biopharma company powered by AI at scale.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Insitro: Insitro applies machine learning to drug discovery and development using large biological datasets and predictive models. Directly comparable to BioMap as an AI-native drug discovery platform serving enterprise pharma customers.
• Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab biology with AI/ML to discover and develop therapeutics at scale. Comparable closed-loop AI+wet-lab model architecture and similar enterprise pharma partnership model.
• Schrödinger, Inc. Schrödinger provides computational chemistry and physics-based simulation software for drug discovery, including AI/ML-augmented platforms. Comparable as an enterprise-licensed AI/ML platform for life science discovery serving top pharma customers.
• Exscientia: Exscientia is an AI-driven precision medicine company using foundation model-like approaches for end-to-end drug discovery. Direct competitor in AI-native pharma discovery partnerships.
• Generate Biomedicines: Generate Biomedicines builds generative AI foundation models for protein design and biologics discovery. Highly comparable as a foundation-model-first AI biotech with similar antibody/protein design focus.
• AbCellera Biologics: AbCellera combines high-throughput antibody discovery platforms with AI/ML data analysis to discover biologics. Comparable enterprise-pharma partnership model and antibody-focused discovery pipeline.
• Iambic Therapeutics (formerly Entos): Iambic develops AI-driven platforms for small-molecule and biologics drug discovery. Comparable AI-first foundation model approach with enterprise pharma partnership model.

Broad incumbents

• Isomorphic Labs: Alphabet-owned commercial venture applying DeepMind's protein folding and biology foundation models to drug discovery. Represents the most direct Big Tech competitor with comparable foundation model approach and unmatched compute resources.
• NVIDIA (BioNeMo): NVIDIA's BioNeMo platform provides foundation models and tools for life science AI development. Indirect competitor as an enabling infrastructure and platform provider that competes for similar enterprise customers.

Emerging players

• Genesis Therapeutics: Genesis Therapeutics applies AI foundation models to small molecule drug discovery, with comparable enterprise pharma partnerships. More narrowly focused on small molecules versus BioMap's broader biologics + multi-vertical scope.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/BiomapI
• LinkedInlinkedin.com/company/biomap2023

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioMap